We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

30 hedge funds and large institutions have $33.5M invested in Xilio Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.05% less ownership

Funds ownership: 4.16% → 4.11% (-0.05%)

6% less funds holding

Funds holding: 32 → 30 (-2)

20% less capital invested

Capital invested by funds: $41.9M → $33.5M (-$8.46M)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
30
Holders Change
-2
Holders Change %
-6.25%
% of All Funds
0.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
5
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$22.8K
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.08K
3
CFB
Cullen/Frost Bankers
Texas
+$261
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$261
5
JP Morgan Chase
JP Morgan Chase
New York
+$37

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$284K
2
Citadel Advisors
Citadel Advisors
Florida
-$34.5K
3
Millennium Management
Millennium Management
New York
-$33.8K
4
NL
NWAM LLC
Washington
-$26.2K
5
LCM
Laurion Capital Management
New York
-$9.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$5.92M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$5.82M – – –
OCA
3
Octagon Capital Advisors
New York
$4.89M -$284K -7,607 -4%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$4.03M – – –
RVM
5
RiverVest Venture Management
Missouri
$3.04M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$3.04M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.88M – – –
AG
8
Artal Group
Luxembourg
$950K – – –
HMC
9
Harvard Management Company
Massachusetts
$878K – – –
TOCUITCONY
10
Trustees of Columbia University in the City of New York
New York
$527K – – –
SCM
11
Soleus Capital Management
Connecticut
$479K – – –
Bank of America
12
Bank of America
North Carolina
$478K -$1.31K -35 -0.2%
Fidelity International
13
Fidelity International
Bermuda
$461K – – –
LCM
14
Laurion Capital Management
New York
$294K -$9.7K -260 -3%
BCM
15
Bridgeway Capital Management
Texas
$233K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$179K +$261 +7 +0.1%
BlackRock
17
BlackRock
New York
$100K -$4.85K -130 -4%
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$55.8K +$22.8K +612 +48%
Morgan Stanley
19
Morgan Stanley
New York
$55.4K -$2.01K -54 -3%
Renaissance Technologies
20
Renaissance Technologies
New York
$44K +$1.08K +29 +2%
Northern Trust
21
Northern Trust
Illinois
$37.6K – – –
State Street
22
State Street
Massachusetts
$33.1K – – –
Charles Schwab
23
Charles Schwab
California
$25.2K – – –
TRCT
24
Tower Research Capital (TRC)
New York
$8.19K -$1.38K -37 -12%
JP Morgan Chase
25
JP Morgan Chase
New York
$5.74K +$37 +1 +0.5%
1
2

XLO Hedge Fund Activity: Q3 2023 in Review

30 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2023, worth a combined $33.5M — down 20% from $41.9M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of XLO and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Dimensional Fund Advisors, adding an estimated $22.8K. The largest seller was Octagon Capital Advisors, cutting an estimated $284K.

  • 30 institutional investors held Xilio Therapeutics (XLO) as of Q3 2023, down from 32 in Q2 2023.
  • Funds reported $33.5M of Xilio Therapeutics stock for Q3 2023, down 20% quarter-over-quarter.
  • 1 fund opened new Xilio Therapeutics positions in Q3 2023 and 3 closed out, a net change of -2 holders.
  • The largest Xilio Therapeutics buyer in Q3 2023 was Dimensional Fund Advisors, an estimated $22.8K added.
  • The largest Xilio Therapeutics seller in Q3 2023 was Octagon Capital Advisors, an estimated $284K sold.

Based on aggregated 13F filings for Q3 2023.